Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in TaxesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Gyre Therapeutics (GYRE) Asset Writedowns and Impairment (2022)

Historic Asset Writedowns and Impairment for Gyre Therapeutics (GYRE) over the last 3 years, with Q1 2022 value amounting to $200000.0.

  • Gyre Therapeutics' Asset Writedowns and Impairment changed N/A to $200000.0 in Q1 2022 from the same period last year, while for Dec 2022 it was $200000.0, marking a year-over-year change of. This contributed to the annual value of $200000.0 for FY2022, which is N/A changed from last year.
  • Per Gyre Therapeutics' latest filing, its Asset Writedowns and Impairment stood at $200000.0 for Q1 2022.
  • In the past 5 years, Gyre Therapeutics' Asset Writedowns and Impairment ranged from a high of $200000.0 in Q1 2022 and a low of $200000.0 during Q1 2022